Experience with degarelix in the treatment of prostate cancer
Degarelix is a gonadotrophin-releasing hormone (GnRH) antagonist for the first-line treatment of androgen-dependent advanced prostate cancer.It has a direct mechanism of action that blocks fp9550bk the action of GnRH on the pituitary with no initial surge in gonadotrophin or testosterone levels.Degarelix is the most extensively studied and widely a